Insulet price target raised to $270 from $260 at BTIG

BTIG analyst Marie Thibault raised the firm’s price target on Insulet (PODD) to $270 from $260 and keeps a Buy rating on the shares after its Q3 earnings beat. The Type 2 label expansion in the U.S. in late August drove strong new customer starts in September and over 25% of new U.S. starts in Q3 were from Type 2 diabetes patients, the analyst tells investors in a research note.